Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial have?
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial has 294 citations in the OpenAlex counts ScholarIQ stores.
When was Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial published?
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial has 2007 year in the ScholarIQ index.
What is the open-access status of Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial?
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial has closed oa status in the ScholarIQ index.
What is the DOI of Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial?
The DOI for Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial is on the source record.
What is the PMID of Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial?
The PMID for Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial is on the source record.
What is the OpenAlex record for Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial?
The OpenAlex for Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial is on the source record.